The influence of cisapride and clarithromycin on QT intervals in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 5, 1998, Pages 542-546

  Van Haarst, Aernout D ^a   Van 'T Klooster, Gerben A E ^b   Van Gerven, Joop M A ^b   Schoemaker, Rik C ^b   Van Oene, Joop C ^b   Burggraaf, Jacobus ^b   Coene, Marie Claire ^b   Cohen, Adam F ^b  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; CLARITHROMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG POTENTIATION; ELECTROCARDIOGRAM; FEMALE; HUMAN; LONG QT SYNDROME; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; STEADY STATE;

EID: 0342968975     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90137-0     Document Type: Article

References (17)

1. McCallum R, Prakash C, Campoli-Richards D, Goa K. Cisapride: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 1988;36:625-81.
2. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995;155:765-8.
3. Lewin MB, Bryant RM, Fenrich AL, Grifka RG. Cisapride-induced long QT interval. J Pediatr 1996;128:279-81.
4. Ahmad RS, Wolfe SM. Cisapride and torsade de pointes [letter]. Lancet 1995;345:508.
5. Ben-David J, Zipes DP. Torsades de pointes and proarrhythmia. Lancet 1993;341:1578-82.
6. Meuldermans W, Van Peer A, Hendrickx J, Lauwers W, Swysen E, Bockx M, et al. Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metab Dispos 1988;16:403-9.
7. Lavrijsen K, van't Klooster G, Heykants J. The role of CYP3A4 in the in-vitro metabolism of cisapride in human liver microsomes and in-vitro and in-vivo interactions of cisapride with co-administered drugs [abstract]. Presented at the Conference on Pharmacogenetics, Bethesda (MD), May 4-5, 1995.
8. Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993;25: 189-204.
9. Schoenberger RA, Haefeli WE, Weiss P, Ritz RF. Association of intravenous erythromycin and potentially fatal ventricular tachycardia with QT prolongation (torsades de pointes). Br Med J 1990;300:1375-6.
10. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;70:353-70.
11. Spicer ST, Liddle C, Chapman JR, Barclay P, Nankivell BJ, Thomas P, et al. The mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol 1997;43:194-6.
12. Paar D, Terjung B, Sauerbruch T. Life-threatening interaction between clarithromycin and disopyramide. Lancet 1997;349:326-7.
13. Thomas M, Macanochie JG, Fletcher E. The dilemma of the prolonged QT interval in early drug studies. Br J Clin Pharmacol 1996;41:77-81.
14. Pratt CM, Ruberg S, Morganroth J, McNutt B, Woodward J, Harris S, et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 1996;131:472-80.
15. Penston JG, McColl KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997;43:223-43.
16. McIntyre AM, Macgregor S, Malek M, Dunbar JA, Hamley JG, Cromarty JA. New patients presenting to their GP with dyspepsia: does Helicobacter pylori eradication minimise the cost of managing these patients? Int J Clin Pract 1997;51:276-81.
17. Annese V, Lombardi G, Frusciante V, Germani U, Andriulli A, Bassotti G. Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin-dependent) diabetes mellitus. Aliment Pharmacol Ther 1997;11:599-603.